Furthermore, recent studies indicated that a pre-chemotherapy for high HBV viral levels is associated with poorer survival in HCC patients with chronic HBV infection [36], and the occurrences of HBV pre-S2Δ large surface proteins in HBV cancer patients are about 30% in Taiwan [37]. This evidence concerns the gene ERVW-1 and hepatocellular carcinoma.